Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Details

Serval ID
serval:BIB_22D46DF377D1
Type
Article: article from journal or magazin.
Collection
Publications
Title
Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Journal
Medecine et maladies infectieuses
Author(s)
Mambie A., Vuotto F., Poitrenaud D., Weyrich P., Cannesson O., Dessein R., Faure K., Guery B., Galpérine T.
ISSN
1769-6690 (Electronic)
ISSN-L
0399-077X
Publication state
Published
Issued date
06/2016
Peer-reviewed
Oui
Volume
46
Number
4
Pages
215-219
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have become a major public health issue worldwide. Cefoxitin is a second-generation cephalosporin and is associated with a strong in vitro activity against ESBL.
We conducted a prospective monocentric cohort study from 2012 to 2015 to evaluate the clinical efficacy and safety of cefoxitin in 15 patients treated for urinary tract infection (UTI) caused by ESBL-E, without any severity criteria.
We included 15 patients; 11 were male patients with defined risk factors for ESBL-E. Ten patients presented with male UTI, three with pyelonephritis, and two with cystitis. Escherichia coli was the predominant pathogen. All patients had a positive outcome with a good tolerance (a skin rash without any sign of severity was observed in one patient). Microbiological cure was obtained in 9 patients out of 10 at the end of treatment.
Cefoxitin is an alternative treatment to carbapenems for urinary tract infections caused by ESBL-producing Enterobacteriaceae.

Pubmed
Create date
23/01/2017 16:47
Last modification date
20/08/2019 13:00
Usage data